🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
This is a multi-center,randomized,phase 3 clinical trial. In the study, HER...
Status
Not Yet Recruiting
Location
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Start Date
2021-02-02
Trial ID
NCT04736589
Treatments Being Tested
To Observe the Efficacy and Safety of Pyrotinib Maleate in Patients With HE...
Status
Unknown
Location
The Second Affiliated hospital of Zhejiang University School of Medical
Start Date
2019-12-17
Trial ID
NCT04380012
Treatments Being Tested
Given that pyrotinib has been proven to exert significant efficacy against ...
Status
Recruiting
Location
Peking University People's Hospital
Start Date
2026-07-06
Trial ID
NCT07600164
Treatments Being Tested
This study is designed to evaluate the efficacy and safety of Camrelizumab ...
Status
Unknown
Location
270 Dongan Road, Fudan University Shanghai Cancer Center
Start Date
2021-12-31
Trial ID
NCT05111444
Treatments Being Tested
This study aims to evaluate the efficacy and safety of pyrotinib in combina...
Status
Active Not Recruiting
Location
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Start Date
2020-05-30
Trial ID
NCT04398914
Treatments Being Tested
Patients with Stage II-III HER2-positive breast cancer will receive three c...
Status
Recruiting
Location
Shanghai Jiaotong University School of Medicine affiliated Ruijin Hospital
Start Date
2026-02-02
Trial ID
NCT07393425
This is a randomised, double-blind multicenter Phase III study for evaluati...
Status
Completed
Location
Peking University People's Hospital
Start Date
2018-07-24
Trial ID
NCT03588091
Treatments Being Tested
This study will explore the efficacy and safety of tislelizumab (PD1 inhibi...
Status
Unknown
Location
Multiple Locations
Start Date
2022-06-20
Trial ID
NCT05350917
Treatments Being Tested
This study evaluates the efficacy and safety of SRT combined with pyrotinib...
Status
Unknown
Location
Jiangxi Cancer Hospital of Nanchang University
Start Date
2022-03-01
Trial ID
NCT05042791
Treatments Being Tested
This study is an open-label, biomarker-integrated umbrella trial designed t...
Status
Not Yet Recruiting
Location
Multiple Locations
Start Date
2026-07-01
Trial ID
NCT07653451
Treatments Being Tested